Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025 Plan to provide a proof of concept data readout in the ...

Q1 2025 Earnings Conference Call May 1, 2025 10:00 AM ETCompany ParticipantsAdam Rohman - Senior Vice President ...

Have top stories from The Daily Pennsylvanian delivered to your inbox every day, Monday through Friday, when Penn classes are in session.